Grey Wolf Therapeutics

Grey Wolf Therapeutics is a clinical-stage biotechnology company focused on developing novel therapies for immuno-oncology and autoimmune diseases. Their unique approach centers on modulating antigen presentation to the immune system, specifically by inhibiting the endoplasmic reticulum aminopeptidases (ERAP1 and ERAP2) that play a crucial role in the antigen presentation pathway. By targeting these enzymes, Grey Wolf aims to generate novel cancer antigens and upregulate certain other neoantigens to enhance tumor visibility for the immune system, as well as to block the production of disease-causing autoantigens to prevent pathogenic immune responses in autoimmune diseases.

Grey Wolf is a UK- and Australia-based company with a growing pipeline of first-in-class ERAP inhibitors. Their lead program, GRWD5769, is a potent and selective oral ERAP1 inhibitor that has shown promise in preclinical studies and is currently being evaluated in a Phase 1/2 clinical trial. The company is also advancing a second ERAP1 inhibitor, GRWD0715, through preclinical development for autoimmune disease. Grey Wolf's research and development efforts are supported by a strong network of collaborations with world-leading academic institutions and contract research organizations. They are committed to translating their innovative technology into transformative therapies for patients with immunologically driven diseases.

Grey Wolf Therapeutics is a clinical-stage, UK- and Australia-based drug discovery and development company committed to developing next-generation therapies for patients with immunologically-driven diseases. Their innovative approach focuses on modulating antigen presentation using ERAP inhibitors to address the source of immune dysfunction in both oncology and autoimmune disease. They are pioneering a novel therapeutic strategy based on a first-of-its-kind approach to antigen modulation by inhibiting the endoplasmic reticulum aminopeptidases (ERAP1 and ERAP2), key proteins in the antigen presentation pathway. This approach has the potential to create entirely new therapeutic opportunities for patients with a range of conditions.

Grey Wolf Therapeutics emphasizes teamwork and collaboration, fostering a culture of open communication and constructive dialogue. They promote innovation and excellence, encouraging individual contributions and a drive to achieve impactful results. This environment is built on a strong sense of momentum and ambition, pushing the team towards shared goals and the development of groundbreaking therapies.

Grey Wolf Therapeutics embraces a culture of diversity, equity, and inclusion, recognizing the value of a diverse workforce. They prioritize collaboration and create a safe environment for all team members to contribute positively, fostering a sense of belonging and encouraging open communication. This approach extends to their scientific team, which includes experts from world-leading academic institutions and contract research organizations, ensuring a breadth of perspectives and expertise.